JMP Securities Reiterates Market Outperform on Taysha Gene Therapies, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $5 price target.
June 20, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Taysha Gene Therapies and maintained a $5 price target, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and the maintenance of a $5 price target by JMP Securities suggests strong confidence in Taysha Gene Therapies' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100